PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31760928-7	2019	Gemcitabine and 5-fluorouracil modulated expression of CSC markers, E-cadherin, and RXRbeta in Panc1 but not in Mia PaCa-2 cells.	gemcitabine	0-11	cadherin 1	Homo sapiens	68-78	
34534538-9	2022	Gemcitabine treatment led to MUC5AC overexpression, resulting in disruption of E-Cadherin/beta-catenin junctions and the nuclear translocation of beta-catenin, which increased c-Myc expression with a concomitant rise in glutamine uptake and glutamate release.	gemcitabine	0-11	cadherin 1	Homo sapiens	79-89	
34955688-10	2021	The level of E-Cadherin, a cell adhesion molecule, increased in Capan1 cells after mEHT + GEM treatment.	gemcitabine	90-93	cadherin 1	Homo sapiens	13-23	
28638102-4	2017	Herein, we demonstrated that overexpression of miR-509-5p and miR-1243 increased the expression of E-cadherin through the suppression of EMT-related gene expression and that drug sensitivity increased with a combination of each of these miRNAs and gemcitabine.	gemcitabine	248-259	cadherin 1	Homo sapiens	99-109	
31186697-1	2019	The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) enrolled in the INNOVATIONS trial, receiving treatment with either erlotinib/bevacizumab (EB) or cisplatin/gemcitabine/bevacizumab (PGB).	gemcitabine	373-384	cadherin 1	Homo sapiens	107-117	
30628651-10	2019	Conversely, miR-301 modulated gemcitabine resistance and induced EMT through the downregulation of cadherin 1 expression.	gemcitabine	30-41	cadherin 1	Homo sapiens	99-109	
29767267-6	2018	Furthermore, cells co-treated with GEM and TSA or VPA exhibited protein levels of E-cadherin or ZO-1 that were higher than those in cells treated with GEM alone, indicating stronger inhibition of EMT.	gemcitabine	35-38	cadherin 1	Homo sapiens	82-92	
19584296-6	2009	Independent validation experiment using five new pancreatic cancer cell lines confirmed that an inverse correlation between E-cadherin and Zeb-1 correlated closely with resistance to gemcitabine, 5-FU, and cisplatin.	gemcitabine	183-194	cadherin 1	Homo sapiens	124-134	
20573371-4	2010	Silencing of E-cadherin was proposed as a mechanism by which enhancer of zeste homologue 2 mediates tumor aggressiveness, and enhancer of zeste homologue 2 depletion has been found to sensitize pancreatic cancer cells to gemcitabine.	gemcitabine	221-232	cadherin 1	Homo sapiens	13-23	
19654291-4	2009	We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells, which showed EMT characteristics such as elongated fibroblastoid morphology, lower expression of epithelial marker E-cadherin, and higher expression of mesenchymal markers such as vimentin and ZEB1.	gemcitabine	123-134	cadherin 1	Homo sapiens	267-277	
22622284-8	2012	DZNeP decreased cell migration, which was additionally reduced by DZNeP/gemcitabine combination (-20% in LPC006, after 8-hour exposure, P < 0.05) and associated with increased E-cadherin mRNA and protein expression.	gemcitabine	72-83	cadherin 1	Homo sapiens	179-189	
17909916-12	2007	Gemcitabine-resistant cells were increased in vimentin and decreased in E-cadherin expression.	gemcitabine	0-11	cadherin 1	Homo sapiens	72-82	
17875687-9	2007	Moreover, up-regulation of E-cadherin by pro-HB-EGF not only resulted in cellular morphologic change but also decreased cell motility and enhanced apoptotic sensitivity in response to gemcitabine-erlotinib treatment.	gemcitabine	184-195	cadherin 1	Homo sapiens	27-37